Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 15Unknown 3Terminated 3Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 9Recurrence 1Oligodendroglioma 1Neoplasms 1Neoplasm Recurrence, Local 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Glioma 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 23Radiosurgery 21Temozolomide 14Bevacizumab 11pembrolizumab 10Specimen Handling 9Nivolumab 8Radiotherapy 7Ipilimumab 7Magnetic Resonance Imaging 6Cyclophosphamide 5Capecitabine 5Blood Specimen Collection 5encorafenib 4Radiation 4Neuropsychological Tests 4Mental Status and Dementia Tests 4Memantine 4Carboplatin 4fludarabine 3fluciclovine F-18 3binimetinib 3abemaciclib 3Watchful Waiting 3Proton Therapy 3Etoposide 3Dexamethasone 3Adrenal Cortex Hormones 3trastuzumab deruxtecan 2sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Brain Neoplasms × Lomustine × Clear all
NCT07100730 2026-04-16

IPAX BrIGHT

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡